Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs.

Su J, Brook RA, Kleinman NL, Corey-Lisle P.

Hepatology. 2010 Aug;52(2):436-42. doi: 10.1002/hep.23726.

PMID:
20683943
2.

Absenteeism and productivity among employees being treated for hepatitis C.

Brook RA, Kleinman NL, Su J, Corey-Lisle PK, Iloeje UH.

Am J Manag Care. 2011 Oct;17(10):657-64.

PMID:
22106459
3.

The impact of gout on work absence and productivity.

Kleinman NL, Brook RA, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, Joseph-Ridge N.

Value Health. 2007 Jul-Aug;10(4):231-7.

4.

Costs and absence of HCV-infected employees by disease stage.

Baran RW, Samp JC, Walker DR, Smeeding JE, Young JW, Kleinman NL, Brook RA.

J Med Econ. 2015;18(9):691-703. doi: 10.3111/13696998.2015.1045423. Epub 2015 Jun 11.

PMID:
26047262
5.

The economic impact of bipolar disorder in an employed population from an employer perspective.

Gardner HH, Kleinman NL, Brook RA, Rajagopalan K, Brizee TJ, Smeeding JE.

J Clin Psychiatry. 2006 Aug;67(8):1209-18.

PMID:
16965198
6.

United States comparative costs and absenteeism of diabetic ophthalmic conditions.

Brook RA, Kleinman NL, Patel S, Smeeding JE, Beren IA, Turpcu A.

Postgrad Med. 2015 Jun;127(5):455-62. doi: 10.1080/00325481.2014.994468. Epub 2014 Dec 31.

PMID:
25549691
7.

The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.

Ivanova JI, Birnbaum HG, Samuels S, Davis M, Phillips AL, Meletiche D.

Pharmacoeconomics. 2009;27(8):681-91. doi: 10.2165/11314700-000000000-00000.

PMID:
19712010
8.

Absenteeism and health-benefit costs among employees with MS.

Brook RA, Rajagopalan K, Kleinman NL, Melkonian AK.

Curr Med Res Opin. 2009 Jun;25(6):1469-76. doi: 10.1185/03007990902905468.

PMID:
19422277
9.

The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database.

Joish VN, Donaldson G, Stockdale W, Oderda GM, Crawley J, Sasane R, Joshua-Gotlib S, Brixner DI.

Curr Med Res Opin. 2005 Apr;21(4):535-44.

PMID:
15899102
10.

The burden of untreated hepatitis C virus infection: a US patients' perspective.

El Khoury AC, Vietri J, Prajapati G.

Dig Dis Sci. 2012 Nov;57(11):2995-3003. doi: 10.1007/s10620-012-2233-1. Epub 2012 Jun 5.

PMID:
22674399
11.

Cohort analysis assessing medical and nonmedical cost associated with obesity in the workplace.

Kleinman N, Abouzaid S, Andersen L, Wang Z, Powers A.

J Occup Environ Med. 2014 Feb;56(2):161-70. doi: 10.1097/JOM.0000000000000099.

PMID:
24451611
12.

Functional dyspepsia impacts absenteeism and direct and indirect costs.

Brook RA, Kleinman NL, Choung RS, Melkonian AK, Smeeding JE, Talley NJ.

Clin Gastroenterol Hepatol. 2010 Jun;8(6):498-503. doi: 10.1016/j.cgh.2010.03.003. Epub 2010 Mar 19.

PMID:
20304102
13.

Annual incremental health benefit costs and absenteeism among employees with and without rheumatoid arthritis.

Kleinman NL, Cifaldi MA, Smeeding JE, Shaw JW, Brook RA.

J Occup Environ Med. 2013 Mar;55(3):240-4. doi: 10.1097/JOM.0b013e318282d310.

PMID:
23471034
14.

Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.

Pike C, Birnbaum HG, Schiller M, Sharma H, Burge R, Edgell ET.

Pharmacoeconomics. 2010;28(5):395-409. doi: 10.2165/11531040-000000000-00000.

PMID:
20402541
15.

Economic burden of epilepsy among the privately insured in the US.

Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Caleo S.

Pharmacoeconomics. 2010;28(8):675-85. doi: 10.2165/11535570-000000000-00000.

PMID:
20623993
16.

Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder.

Secnik K, Swensen A, Lage MJ.

Pharmacoeconomics. 2005;23(1):93-102.

PMID:
15693731
17.

Persistence and adherence with urinary antispasmodic medications among employees and the impact of adherence on costs and absenteeism.

Kleinman NL, Odell K, Chen CI, Atkinson A, Zou KH.

J Manag Care Spec Pharm. 2014 Oct;20(10):1047-56.

18.

Cost of gastro-oesophageal reflux disease to the employer: a perspective from the United States.

Brook RA, Wahlqvist P, Kleinman NL, Wallander MA, Campbell SM, Smeeding JE.

Aliment Pharmacol Ther. 2007 Sep 15;26(6):889-98.

19.

Direct and indirect costs among employees with diabetic retinopathy in the United States.

Lee LJ, Yu AP, Cahill KE, Oglesby AK, Tang J, Qiu Y, Birnbaum HG.

Curr Med Res Opin. 2008 May;24(5):1549-59. doi: 10.1185/030079908X297303 . Epub 2008 Apr 15.

PMID:
18416887
20.

Medical and productivity costs of anxiety disorders: case control study.

Marciniak M, Lage MJ, Landbloom RP, Dunayevich E, Bowman L.

Depress Anxiety. 2004;19(2):112-20.

PMID:
15022146

Supplemental Content

Support Center